Abstract
The National Lipid Association's (NLA) Muscle Safety Expert Panel was charged with the duty of examining the definitions, causative factors, and management of statin myopathy. The Panel was asked to use its evidence-based findings to form recommendations in response to a series of specific questions posed by the Task Force. The panel was composed of a clinical cardiologist, an exercise physiologist and skeletal muscle expert, and an expert in preventive cardiology who also examined skeletal muscle complications of statin use.
MeSH terms
-
Biopsy
-
Creatine Kinase / analysis
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Drug Labeling
-
Drug Therapy, Combination
-
Evidence-Based Medicine
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics
-
Muscle, Skeletal / pathology
-
Muscular Diseases / chemically induced*
-
Muscular Diseases / classification
-
Muscular Diseases / prevention & control
Substances
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Creatine Kinase